The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
Post filled. Careers We are not currently actively recruiting but are always interested to hear from experienced quantitative pharmacologists or biologists with a background in oncology. If this is you, please do contact us. http://www.physiomics-plc.com/about-us/careers/
Presenting new data from a number of high priority clinical development programs across its oncology portfolio at ASCO 2018 this week.. https://www.merckgroup.com/en/news.html#businessUnit-business:corporate,newsType-ALL,year-ALL,month-ALL,page-0,filter-news
Merck KGAa showcasing their progress and other options with their Oncology Pipeline at ASCO 2018 Annual Meeting coming June 1-5. Numerous Abstracts, Posters and Presentations being shown. Second item down https://www.merckgroup.com/en/news.html#businessUnit-business:corporate,newsType-ALL,year-ALL,month-ALL,page-0,filter-news
Who does she think she is,claiming she is the one that discovered it was Merck Serono KGAa and not Merck US.. It has been known for years Physiomics had contract with Merck KGAa to develope VT Clinical. RNS from 3rd March 2015 First contract for a clinical version of our Virtual Tumour model (�Virtual Tumour Clinical�) with Global Pharmaceutical Company, Merck (Merck Serono) Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has signed its first contract for developing Virtual Tumour Clinical with a global pharmaceutical company. The client is Merck Serono, the biopharmaceutical division of Merck, Germany. Also has been on Physiomics site under " Our Partners":- Merck Serono :- After having worked on a number of pre-clinical projects for several years, Physiomics has signed in 2015 its first contract for developing Virtual Tumour Clinical with Merck Serono. Physiomics scientists will be working closely with Merck Serono scientists to develop and calibrate a model that can predict optimal combination partners for both marketed and pipeline drugs.
http://www.proactiveinvestors.co.uk/companies/news/196925/physiomics-ready-to-build-on-merck-serono-landmark-196925.html Physiomics ready to build on Merck Serono landmark WATCH: Physiomics PLC: Personalised medicines will build on momentum from recent pharma deals Revenues on the rise In the meantime, the contracts already won this year should this year produce a significant jump in revenues. Turnover in the year to June 2017 was �270,000 with a net loss of �400,000 but some of the �500,000 from Merck will fall into this calendar year in addition to the �153,000 from the three new contracts plus the �68,00 Innovate grant. At a price of 6.15p, the company is valued at a lowly �3.6mln, but Millen points out that is five times more than a year ago. �Momentum is building and we are establishing a history of delivering what we say.�
All in here, 328 pages https://www.merckgroup.com/content/dam/web/corporate/non-images/investors/reports-and-financials/earnings-materials/2017-q4/en/2017-Q4-Report-EN.pdf
Merck�s Focus on Cancer Our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer worldwide. At Merck, helping people fight cancer is our passion and supporting accessibility to our cancer medicines is our commitment. Our focus is on pursuing research in oncology and we are accelerating every step in the journey � from lab to clinic � to potentially bring new hope to people with cancer. As part of our focus on cancer, Merck is committed to exploring the potential of immuno-oncology with one of the fastest-growing development programs in the industry evaluating oncology medicines in more than 30 tumor types. We also continue to strengthen our oncology portfolio through strategic acquisitions and are prioritizing the development of several promising candidates with the potential to improve the treatment of advanced cancers. For more information about our oncology clinical trials, visit www.merck.com/clinicaltrials. Liked this part. As part of our focus on cancer, Merck is committed to exploring the potential of immuno-oncology with one of the fastest-growing development programs in the industry evaluating oncology medicines in more than 30 tumor types.
Jim Millen explains Physiomics approach to personlised medicine. https://m.youtube.com/watch?v=R-V0cD7-4JY
Look what company had 1st Quarter results yesterday, digest and research relevant avenues, notice time of majority buys today!!!
You are all falling into her ploy by replying back to her, ignore her.
From report 2016, following can be found on page 9. Clinical projects projection value £150K + vs pre-clinical value £50K https://www.scribd.com/document/341300019/Physiomics-Initiation-27102016
From rns 28 nov 2017 Completion of vt clinical project with Merck. Physiomics can now confirm that it has been working with Merck since March 2012, during which time it has completed twelve projects involving pre-clinical and more recently clinical predictions, with other projects in progress. If you research you will find other trials being carried out by Merck.
35k a pop is for pre-clinical trials. Clinical trials are for a few 100k a pop, at moment being carried for Merck.
Following is a Fake item about Merck 2024 interesting read item 18 and 19 Translational Data Science at Merck Chris L. Waller, Ph.D. Executive Director and Head, Scientific Modeling Platforms� https://www.slideshare.net/wallerc/translational-data-scienceclean-67882721
Jim has got a 5 min slot for company update on 24th. https://www.biotrinity.com/sites/default/files/BioLaunchPad%20Programme%20v4%209April2018.pdf
Physiomics to Present at BioTrinity 2018 Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to announce that it will attend BioTrinity 2018. BioTrinity is one of Europe’s leading biopartnering and investment conferences, to be held on 23-25 April at the Novotel London West. In addition to participating in a number of partnering meetings, Dr Jim Millen, CEO, will present a company update at 12.25pm on Tuesday 24th April.
You are missing the point, the results were obtained by what has been developed. The above key results as well as others pertaining to attempted and successful surgery can all be explored using the dynamic web-based interface developed.
Conclusion We have created a DSS tool using historical data to support Cancer Multidisciplinary Teams in understanding how key variables affect treatment choices and how these in turn relate to disease outcomes. The tool has the potential to be used to support the optimisation of treatment for individual patients based on the characteristics of their disease. Thus the DSS tool developed is a first step to personalised treatment of cancer.
I posted on other bb other day Abstract now available to read. LB-025 / 5 - A decision support system for the treatment of esophageal cancer http://www.abstractsonline.com/pp8/#!/4562/presentation/10434
too late.